FrancophonIA/ELRC3.0 huggingface dataset:
English: Because PegIntron is linked to side effects such as depression, patients must be closely monitored during treatment.
Estonian: Et PegIntroniga seonduvad sellised kõrvalnähud nagu depressioon, peab patsiente ravi ajal tähelepanelikult jälgima.
English: The CHMP decided that PegIntron's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et PegIntroni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: This document is a summary of the European Public Assessment Report (EPAR) for PegIntron.
Estonian: See on ravimi PegIntron Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about PegIntron:
Estonian: Muu teave PegIntroni kohta
English: For more information about treatment with PegIntron, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate PegIntroniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In children and adolescents receiving PegIntron in combination with ribavirin, side effects were similar to adults, although reduced growth was also seen in more than 1 patient in 10.
Estonian: Lastel ja noorukitel, kes said PegIntroni koos ribaviriiniga, olid kõrvalnähud samasugused kui täiskasvanutel, kuigi ka kasvupeetust esines enam kui 1 patsiendil 10st.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for PegIntron.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: In adults (aged 18 years and older), PegIntron can be used in patients who have not been treated before or whose previous treatment failed.
Estonian: PegIntroni tohib kasutada täiskasvanud (vähemalt 18-aastastel) patsientidel, keda varem ei ole ravitud või kelle varasem ravi on ebaõnnestunud.
English: The combination of PegIntron and ribavirin has also been studied in one study involving 1,354 adults whose previous treatment had failed and in one study involving 107 children and adolescents aged between three and 17 years who had not been treated before.
Estonian: PegIntroni ja ribaviriini kombinatsiooni uuriti ka uuringus, kus osales 1354 täiskasvanut, kelle varasem ravi oli ebaõnnestunud, ja uuringus, kus osales 107 varem ravimata 3-17-aastast last ja noorukit.
English: PegIntron is also linked to weight loss and reduced growth in children and adolescents.
Estonian: PegIntroni seostatakse lastel ja noorukitel ka kehakaalu kaotuse ja kasvupeetusega.
English: PegIntron must not be used in patients with a severe medical condition, severe liver problems, thyroid disease that is not controlled, epilepsy or other central nervous system problems.
Estonian: PegIntroni ei tohi kasutada patsiendid, kellel on raske terviseseisund, rasked maksaprobleemid, ravile allumatu kilpnäärmehaigus või epilepsia või muud kesknärvisüsteemi häired.
English: PegIntron must not be used in people who are hypersensitive (allergic) to any interferon or any of the other ingredients.
Estonian: PegIntroni ei tohi kasutada patsiendid, kes on mis tahes interferooni või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: What is PegIntron?
Estonian: Mis on PegIntron?
English: For the full list of all side effects reported with PegIntron, see the package leaflet.
Estonian: PegIntroni kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Why has PegIntron been approved?
Estonian: Miks PegIntron heaks kiideti?
English: The combination of PegIntron with ribavirin was effective in patients with cirrhosis and in patients infected with HIV.
Estonian: PegIntroni ja ribaviriini kombinatsioon oli efektiivne tsirroosiga ja HIVnakkusega patsientidel.
English: PegIntron, with or without ribavirin, has been compared with interferon alfa-2b in five main studies involving a total of over 6,000 adults with hepatitis C who had not been treated before, including 328 patients with cirrhosis and 507 patients also infected with HIV.
Estonian: PegIntroni kasutamist koos ribaviriiniga või ilma võrreldi alfa-2b-interferooniga viies põhiuuringus, milles osales kokku üle 6000 täiskasvanud patsiendi, kellel oli C-hepatiit ja keda varem ei olnud ravitud, sh 328 tsirroosiga patsienti ja 507 patsienti, kellel oli ka HIV-nakkus.
English: The interferon alfa-2b in PegIntron is produced by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce interferon alfa-2b.
Estonian: PegIntronis sisalduvat alfa2b-interferooni valmistatakse rekombinant-DNA-tehnika abil: seda toodab bakter, millele on lisatud alfa-2b-interferooni teket võimaldav geen (DNA).
English: PegIntron peginterferon alfa-2b
Estonian: PegIntron alfa-2b-peginterferoon
English: In other adults with hepatitis C virus in their blood, including patients also infected with human immunodeficiency virus (HIV), PegIntron is given either with ribavirin (dual therapy) or on its own if they cannot take ribavirin.
Estonian: Teistele täiskasvanud patsientidele, kelle veres on C-hepatiidi viirus, sh neile, kes on nakatunud ka inimese immuunpuudulikkuse viirusega (HIV), manustatakse PegIntroni koos ribaviriiniga (ravi kahe preparaadiga) või ainsa ravimina, kui patsient ribaviriini ei talu.
English: What is the risk associated with PegIntron?
Estonian: Mis riskid PegIntroniga kaasnevad?
English: PegIntron is a medicine that contains the active substance peginterferon alfa-2b.
Estonian: PegIntron on ravim, mis sisaldab toimeainena alfa-2b-peginterferooni.
English: Depending on the severity of the side effects treatment may have to be stopped altogether (including boceprevir).Patients can inject themselves once they have been trained appropriately.
Estonian: Sõltuvalt kõrvalnähtude raskusest võib olla vaja ravi (sh ka botsepreviiri manustamine) täielikult lõpetada.
English: PegIntron can be given in a triple therapy combination with ribavirin and boceprevir to adults with type 1 hepatitis C whose liver is damaged but still able to work normally (compensated liver disease).
Estonian: PegIntroni tohib anda koos ribaviriini ja botsepreviiriga (ravi kolme preparaadiga) täiskasvanud patsientidele 1. tüüpi C-hepatiidi korral, kui patsiendi maks on kahjustatud, ent võimeline normaalselt talitlema (kompenseeritud maksahaigus).
English: In adults, PegIntron was more effective than interferon alfa-2b in patients who had not been treated before, with around a quarter of the patients responding to PegIntron alone and around a half responding to the combination of PegIntron and ribavirin.
Estonian: Varem ravimata täiskasvanud patsientidel oli PegIntron efektiivsem kui alfa-2b-interferoon: ligikaudu veerandil patsientidest tekkis ravivastus üksnes PegIntronile ning ligikaudu pooltel PegIntroni ja ribaviriini kombinatsioonile.
English: PegIntron is used to treat long-term hepatitis C (a disease of the liver due to infection with the hepatitis C virus) in patients aged three years and older.
Estonian: Ravimit PegIntron kasutatakse kroonilise (pikaajalise) C-hepatiidi (C-hepatiidi viiruse nakkusest põhjustatud maksahaigus) raviks vähemalt 3-aastastel patsientidel.
English: Triple therapy led to an increase of about 30% in the number of previously untreated early responders who were cured.
Estonian: Ravi kolme preparaadiga suurendas ravile kiiresti reageerinud varem ravimata ja tervenenud patsientide arvu ligikaudu 30% võrra.
English: How does PegIntron work?
Estonian: Kuidas PegIntron toimib?
English: What benefit has PegIntron shown during the studies?
Estonian: Milles seisneb uuringute põhjal PegIntroni kasulikkus?
English: Two main studies involving 1,503 adult patients with type 1 hepatitis C and compensated liver disease investigated the effect of PegIntron in a triple therapy combination with ribavirin and boceprevir compared with PegIntron and ribavirin alone.
Estonian: Kahes põhiuuringus (1503 täiskasvanud patsienti, kellel oli 1. tüüpi C-hepatiit ja kompenseeritud maksahaigus) hinnati koos ribaviriini ning botsepreviiriga manustatud PegIntroni toimet (ravi kolme preparaadiga) ainult PegIntroni ja ribaviriini toimega.
English: The active substance in PegIntron, peginterferon alfa-2b, belongs to the group ‘interferons'.
Estonian: PegIntroni toimeaine alfa-2b-peginterferoon kuulub interferoonide rühma.
English: The Committee noted that the dual combination with ribavirin was shown to be effective against longterm hepatitis C virus infection in adults and children.
Estonian: Inimravimite komitee märkis, et on tõendatud kahe preparaadiga ravi (PegIntron koos ribaviriiniga) efektiivsus täiskasvanutel ja lastel kroonilise C-hepatiidi nakkuse korral.
English: What is PegIntron used for?
Estonian: Milleks PegIntroni kasutatakse?
English: Treatment with PegIntron should be started and supervised by a doctor who has experience in the management of patients with hepatitis C. PegIntron is given once a week as an injection under the skin.
Estonian: Ravi PegIntroniga peab alustama üksnes C-hepatiidiga patsientide ravis kogenud arst ning ravi peab toimuma tema järelevalve all.
English: How is PegIntron used?
Estonian: Kuidas PegIntroni kasutatakse?
English: In the studies on triple therapy in patients with type 1 hepatitis C and compensated liver disease, PegIntron in combination with ribavirin and boceprevir was shown to be more effective than the dual combination of PegIntron with ribavirin alone.
Estonian: 1. tüüpi C-hepatiidi ja kompenseeritud maksahaigusega patsientide ravi kolme preparaadiga (PegIntron kombinatsioonis ribaviriini ning botsepreviiriga) oli efektiivsem kui ravi kahe preparaadiga (PegIntron koos ribaviriiniga).
English: How has PegIntron been studied?
Estonian: Kuidas PegIntroni uuriti?
English: The doses of ribavirin and PegIntron may need to be adjusted for patients who experience side effects.
Estonian: Kui patsiendil tekivad kõrvalnähud, võib olla vaja ribaviriini ja PegIntroni annuseid kohandada.
English: Around a quarter of the adults whose previous treatment had failed and around two-thirds of the children and adolescents responded to treatment with PegIntron and ribavirin.
Estonian: PegIntroni ja ribaviriini kombinatsioonile tekkis ravivastus ligikaudu veerandil täiskasvanuist, kelle varasem ravi oli ebaõnnestunud, ning ligikaudu kahel kolmandikul lastest ja noorukitest.
English: In PegIntron, the interferon alfa-2b has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Estonian: Alfa-2b-interferoon on PegIntronis pegüleeritud (seotud polüetüleenglükooliga).
English: The medicine can only be obtained with a prescription.
Estonian: Pärast asjakohase väljaõppe saamist võivad patsiendid endale ravimit ise süstida.
English: The Member States shall ensure that the MAH provides all physicians who are expected to prescribe or use Tamiflu a Direct Healthcare Professional Communication (DHPC) letter, the text of which is appended to the CHMP assessment report.
Estonian: Liikmesriigid tagavad, et müügiloa hoidja saadab kõikidele arstidele, kes võivad hakata Tamiflu'd välja kirjutama või kasutama, tervishoiutöötajatele mõeldud kirja, mille tekst on lisatud inimravimite komitee hindamisaruandele.
English: The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented.
Estonian: Liikmesriigid peavad tagama kõikide allpool kirjeldatud ravimpreparaadi ohutu ja efektiivse kasutamise tingimuste või piirangute täitmise.
English: The Member States shall agree with the MAH the communication plan for the DHPC letter.
Estonian: Liikmesriigid lepivad müügiloa hoidjaga kokku tervishoiutöötajatele mõeldud kirja levitamise kava.
English: CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
Estonian: RAVIMPREPARAADI OHUTU JA EFEKTIIVSE KASUTAMISE TINGIMUSED VÕI PIIRANGUD, MIDA TULEB RAKENDADA LIIKMESRIIKIDES
English: ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
Estonian: LISA RAVIMPREPARAADI OHUTU JA EFEKTIIVSE KASUTAMISE TINGIMUSED VÕI PIIRANGUD, MIDA TULEB RAKENDADA LIIKMESRIIKIDES
English: The doctor may decide that patients or their caregivers can inject the medicine themselves after they have been properly trained.
Estonian: Arst võib otsustada, et patsient või tema hooldaja tohib süstida ravimit ka ise, kui nad on saanud asjakohase väljaõppe.
English: What measures are being taken to ensure the safe and effective use of Takhzyro?
Estonian: Mis meetmed võetakse, et tagada Takhzyro ohutu ja efektiivne kasutamine?
English: The European Medicines Agency therefore decided that Takhzyro's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Takhzyro kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Overall, the safety profile was considered acceptable.
Estonian: Takhzyro ohutusprofiili peeti üldiselt vastuvõetavaks.
English: Further information on the orphan designation can be found here: ema.europa.eu/medicines/human/orphan-designations/eu3151551
Estonian: Lisateave harvikravimiks nimetatud ravimi kohta on leitav: ema.europa.eu/medicines/human/orphandesignations/eu3151551
English: Further information on Takhzyro can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Takhzyro.
Estonian: Lisateave Takhzyro kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Takhzyro.
English: Other information about Takhzyro
Estonian: Muu teave Takhzyro kohta
English: The recommended starting dose of Takhzyro is 300 mg every 2 weeks.
Estonian: Takhzyro soovitatav algannus on 300 mg iga 2 nädala järel.
English: If the patient remains free of attacks with the two-weekly dose, the doctor can reduce the frequency to once every 4 weeks.
Estonian: Kui patsiendile ei teki haigushooge ühe annuse kasutamisel iga kahe nädala järel, võib arst sagedust vähendada ühe annuseni iga 4 nädala järel.
English: Takhzyro is effective in preventing angioedema attacks and the fact that it only needs to be given every 2 or 4 weeks was considered an advantage over existing treatments.
Estonian: Takhzyro on efektiivne angioödeemi hoogude ennetamisel ning asjaolu, et seda on vaja manustada ainult kord 2 või 4 nädala järel, peeti eeliseks muude olemasolevate ravivõimaluste ees.
English: As for all medicines, data on the use of Takhzyro are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Takhzyro kasutamise kohta pidevat järelevalvet.
English: Side effects reported with Takhzyro are carefully evaluated and any necessary action taken to protect patients.
Estonian: Takhzyro kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: For more information about using Takhzyro, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Takhzyro kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Takhzyro have been included in the summary of product characteristics and the package leaflet.
Estonian: Takhzyro ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Patients experienced on average 0.3 attacks per month when given Takhzyro injections every 2 weeks and 0.5 attacks when given injections every 4 weeks.
Estonian: Patsientidel esines keskmiselt 0,3 hoogu kuus, kui neile süstiti Takhzyrot iga 2 nädala järel, ning 0,5 hoogu kuus, kui neile süstiti ravimit iga 4 nädala järel.
English: What is Takhzyro and what is it used for?
Estonian: Mis on Takhzyro ja milleks seda kasutatakse?
English: Patients with angioedema have rapid swelling under the skin in areas such as the face, throat, arms and legs.
Estonian: Angioödeemiga patsientidel tekib kiiresti näo-, kõri-, käte ja jalgade piirkonna nahaalune turse.
English: The most common side effects with Takhzyro (which may affect more than 1 patient in 10) are reactions at the site of injection including erythema (redness), bruising and pain.
Estonian: Takhzyro kõige sagedamad kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) on süstekoha reaktsioonid, sealhulgas erüteem (punetus), verevalumid ja valu.
English: Hereditary angioedema is rare, and Takhzyro was designated an ‘orphan medicine' (a medicine used in rare diseases) on 9 October 2015.
Estonian: Pärilik angioödeem esineb harva ja Takhzyro nimetati 9. oktoobril 2015 harvikravimiks.
English: What are the risks associated with Takhzyro?
Estonian: Mis riskid Takhzyroga kaasnevad?
English: For the full list of side effects and restrictions with Takhzyro, see the package leaflet.
Estonian: Takhzyro kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Takhzyro is a medicine used to prevent attacks of hereditary angioedema in patients aged 12 years and over.
Estonian: Takhzyro on ravim, mida kasutatakse päriliku angioödeemi hoogude ennetamiseks vähemalt 12aastastel patsientidel.
English: Takhzyro can only be obtained with a prescription and should be started under supervision of a doctor experienced in managing hereditary angioedema.
Estonian: Takhzyro on retseptiravim ning ravi tohib alustada ainult päriliku angioödeemi ravis kogenud arsti järelevalve all.
English: By blocking the actions of kallikrein, lanadelumab helps to prevent the swelling and related symptoms of angioedema.
Estonian: Blokeerides kallikreiini toimet, aitab lanadelumaab ennetada turse teket ning kaasuvaid angioödeemi sümptomeid.
English: EMA/734573/2018
Estonian: Takhzyro (lanadelumaab) EMA/734573/2018
English: Takhzyro contains the active substance lanadelumab.
Estonian: Takhzyro sisaldab toimeainena lanadelumaabi.
English: How does Takhzyro work?
Estonian: Kuidas Takhzyro toimib?
English: Attacks of hereditary angioedema can be life threatening when the swelling around the throat presses against the airway.
Estonian: Päriliku angioödeemi hood on eluohtlikud, kui kõripiirkonna tursest tekkinud surve sulgeb hingamisteed.
English: Takhzyro is given as an injection under the skin, preferably in the abdomen (belly), thighs or upper arms.
Estonian: Takhzyrot manustatakse nahaaluse süstina, eelistatult kõhupiirkonda, reide või õlavarde.
English: How is Takhzyro used?
Estonian: Kuidas Takhzyrot kasutatakse?
English: What benefits of Takhzyro have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Takhzyro kasulikkus?
English: Takhzyro was found to be effective in reducing the number of angioedema attacks in a main study in 126 adults and children above 12 years of age with hereditary angioedema.
Estonian: Põhiuuringus, milles osales 126 päriliku angioödeemiga täiskasvanut ja üle 12-aastast last, tõendati, et Takhzyro vähendab efektiivselt angioödeemi hooge.
English: An overview of Takhzyro and why it is authorised in the EU
Estonian: Ülevaade ravimist Takhzyro ja ELis müügiloa väljastamise põhjendus
English: This compared with 2 attacks per month for patients on placebo (a dummy treatment).
Estonian: Platseebot (näiv ravim) saanud patsientidel esines sellega võrreldes 2 hoogu kuus.
English: The active substance in Takhzyro, lanadelumab, works by attaching to and blocking an enzyme in the blood called 'kallikrein', which has several functions, including increasing levels of bradykinin.
Estonian: Takhzyro toimeaine lanadelumaab toimib, seondudes vererakkude ensüümi kallikreiiniga ja seda blokeerides.
English: Patients with hereditary angioedema have high levels of a substance called ‘bradykinin', which causes blood vessels to widen and leak fluid into the surrounding tissue leading to the swelling attacks seen in angioedema.
Estonian: Päriliku angioödeemiga patsientide organismis on palju ainet, mida nimetatakse bradükiniiniks.
English: Key results from all four studies are summarised in table 4.
Estonian: Kõigi nelja uuringu tähtsaimad tulemused on kokku võetud tabelis 4.
English: Your doctor will decide if you should receive other treatment at the same time.
Estonian: Teie arst otsustab, kas te vajate samal ajal muud ravi.
English: <Justification for not including Braille accepted.>
Estonian: Põhjendus Braille' mitte lisamiseks.
English: • if you think you may need any vaccinations in the near future, including vaccinations for travel to other countries.
Estonian: • kui te arvate, et võite lähiajal vajada mõnda vaktsiini, sealhulgas vaktsiine, mida manustatakse enne teistesse riikidesse reisimist.
English: p-value (Wald test, not
Estonian: p-väärtus (Waldi test, korrigeerimata)
English: Rituzena may also cause changes in laboratory tests carried out by your doctor.
Estonian: Rituzena võib põhjustada ka muutusi teie arsti poolt tehtavates laborianalüüsides.
English: The safety and efficacy of Rituzena in children below 18 years has not been established.
Estonian: Rituzena ohutus ja efektiivsus lastel vanuses alla 18 aasta ei ole tõestatud.
English: • The need to carry the card at all times and to show the card to all treating health
Estonian: Vajadus kanda kaarti endaga kogu aeg kaasas ja näidata seda kõikidele ravis osalevatele
English: Rituzena is indicated in adults for the following indications:
Estonian: Rituzena on näidustatud täiskasvanutele järgmistel näidustustel:
English: Date of first authorisation: 13 July 2017
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 13. juuli 2017
English: You may be asked not to take these other medicines 12 hours before you are given Rituzena.
Estonian: Teil võidakse paluda mitte võtta neid ravimeid 12 tundi enne Rituzena manustamist.
English: Treatment with Rituzena uses four separate infusions given at weekly intervals.
Estonian: Rituzena-ravi koosneb neljast eraldi infusioonist, mis manustatakse nädalaste vahedega.
English: • The need to check, prior to Rituzena treatment, for infections, for immunosuppression, for prior/current medication affecting the immune system and recent history of, or planned,
Estonian: • Vajadus enne Rituzena'ga ravi alustamist kontrollida infektsioonide, immunosupressiooni, immuunsüsteemi mõjutavate ravimite eelneva/praeguse kasutamise ning hiljuti tehtud või planeeritava vaktsineerimise suhtes.
English: What Rituzena looks like and contents of the pack
Estonian: Kuidas Rituzena välja näeb ja pakendi sisu
English: If you can get pregnant, you and your partner must use an effective method of contraception while using Rituzena.
Estonian: Kui te olete rasestuda võiv naine, peate teie ja teie partner kasutama Rituzena-ravi ajal tõhusaid rasestumisvastaseid meetodeid.
English: The clinical relevance of HACA formation in rituximab-treated patients is unclear.
Estonian: HACA tekke kliiniline tähtsus rituksimabiga ravitud patsientidel on ebaselge.
English: Of 356 patients evaluated for HACA, 1.1 % (4 patients) were positive.
Estonian: 356-st uuritud patsiendist oli vähem kui 1,1 %-l (4 patsiendil) HACA positiivne.
English: Pharmacotherapeutic group: antineoplastic agents, monoclonal antibodies, ATC code: L01XC02
Estonian: Farmakoterapeutiline rühm: kasvajavastased ained, monoklonaalsed antikehad, ATC-kood: L01XC02
English: When you are treated with Rituzena in combination with chemotherapy, you will receive Rituzena every 28 days until you have received 6 doses.
Estonian: Kui te saate Rituzena't kombinatsioonis keemiaraviga, saate Rituzena't iga 28 päeva järel, kuni olete saanud 6 annust.
English: Tell your doctor immediately if you get signs of an infection including:
Estonian: Infektsioonid Teavitage oma arsti otsekohe sellest, kui teil tekivad infektsiooninähud, sealhulgas: